Latest Breaking News On - Prnewswire cellcentric - Page 1 : comparemela.com

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma

CellCentric presents early clinical data at ASH: inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomPrnewswire cellcentricTim somervaillePaul richardsonAzim suraniLeif bergsagelDepartment of internal medicineUniversity of manchesterGurdon instituteHarvard medical schoolErnestn morial convention centerAmerican society of haematologyTakeda pharmaceuticalsUniversity of cambridgeClinical research

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesAndrew hughesPrnewswire cellcentricTim somervailleAzim suraniUniversity of cambridgeTakeda pharmaceuticalsUniversity of manchesterGurdon instituteErnestn morial convention centerAmerican society of haematologyNew orleansChief investigatorProfessor tim somervailleAmerican society

CellCentric Strengthens Leadership Team

/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.

United kingdomAndrew hughesPrnewswire cellcentricKris freseDevelopment adviserAstrazeneca pharmaceuticalsScientist at cancer research united kingdomCancer biomarker centre preclinical pharmacology teamUniversity of manchesterCancer research united kingdomChief development adviserCancer biologyAssociate scientistCancer biomarker centre preclinical pharmacologyHonorary professorExperimental cancer medicine

CellCentric secures investment from American Cancer Society s impact venture capital fund to advance inobrodib, its ground-breaking p300/CBP targeted therapy

/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.

United statesUnited kingdomNorth lanarkshireAlice pomponioPrnewswire cellcentricJason dingesInternational nameMorningside investmentsAmerican cancer society brightedgeMorningside technology advisoryAmerican cancer societyWorld health organisationAmerican cancerAndrogen receptorInternational non proprietary nameManaging director

CellCentric secures investment from American Cancer Society s impact venture capital fund to advance inobrodib, its ground-breaking p300/CBP targeted therapy

/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.

United statesUnited kingdomNorth lanarkshireAlice pomponioPrnewswire cellcentricJason dingesInternational nameMorningside investmentsAmerican cancer society brightedgeMorningside technology advisoryAmerican cancer societyWorld health organisationAmerican cancerAndrogen receptorInternational non proprietary nameManaging director